The National Pharmaceutical Pricing Authority (NPPA), on July 2026, fixed the retail price of Each Uncoated Bilayered Tablet containing Desvenlafaxine Succinate USP equivalent to Desvenlafaxine 50 mg (Extended-Release) and Clonazepam IP 0.5 mg, manufactured by M/s Pure and Cure Healthcare Pvt. Ltd. and marketed by M/s Mankind Pharma Ltd. The retail price has been determined under Paragraph 5 of the Drugs (Prices Control) Order (DPCO), 2013 based on November 2025 market data.
The NPPA has fixed the retail price at ₹17.47 per tablet (excluding GST) after calculating the average price to retailers (PTR) of eligible brands with a market share of 1% or above and adding the prescribed 16% retailer margin, in accordance with the pricing methodology under DPCO, 2013.
Manufacturers and marketers are required to market the formulation at or below the notified retail price, with GST, wherever applicable, chargeable in addition to the notified price, in compliance with the provisions of the Drugs (Prices Control) Order, 2013.
[File No. 19(5257)/2026/DP/NPPA/Div.II]
